P. Swiderski

Local CpG-Stat3 siRNA treatment improves antitumor effects of checkpoint inhibitors

This study shows that local CpG-Stat3 siRNA treatment enhances checkpoint inhibitor efficacy in mouse tumor models by improving T-cell responses.

Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3

This paper develops a PROTAC-based strategy to selectively degrade activated STAT3 in specific cell types, showing efficacy in reducing STAT3 levels and tumor growth in lymphoma models.